Learning Studios, symposia offer latest advances
Learning Studios and symposia provide a unique opportunity for companies in the field of cardiology to share their latest advances in cardiovascular practices, services and technologies.
Here are the opportunities that will be presented at Scientific Sessions. Check the Mobile App for updates and a complete list of programming. (List current as of Oct. 22, 2020.)
Friday, Nov. 13
8-8:45 a.m.
Move More Break
1:30-2:15 p.m.
Importance of Real-World Evidence in Understanding Current Lipid Management in Patients With ASCVD: A Focus on MI (LS.01)
Sponsored by Amgen, Inc.
1:30-2:15 p.m.
Selecting a First-Choice Therapy for Systolic HF: Meeting the Burden of Proof (LS.02)
Sponsored by Novartis Pharmaceuticals Corporation
1:30-2:15 p.m.
Transthyretin Cardiac Amyloidosis (ATTR-CM) Considerations and Clinical Challenges: Identifying, Confirming and Treating Patients (LS.03)
Sponsored by Pfizer, Inc.
2:30-3:15 p.m.
Exploring Worsening Heart Failure Events in Patients With Chronic Heart Failure With Reduced Ejection Fraction (LS.06)
Sponsored by Merck Sharp and Dohme Corp.
2:45-3:30 p.m.
The Next Horizon in the Heart Failure Treatment Paradigm for Patients With HFrEF: Results of the Landmark DAPA-HF Clinical Trial (LS.04)
Sponsored by AstraZeneca Pharmaceuticals LP
2:45-3:30 p.m.
The Cardiac Sarcomere in HFrEF and HCM: From Bedside to Bench (LS.05)
Sponsored by Cytokinetics, Inc.
5-6:30 p.m.*
Getting to the Heart of Diabetes: The Role of GLP-1 Receptor Agonists in Reducing Cardiovascular Risk (SS.07)
Sponsored by Lilly
5-6:30 p.m.*
Optimizing Outcomes in VTE Management: Collaborating Across the Continuum (SS.11)
Sponsored by The Bristol-Myers Squibb & Pfizer Alliance
Saturday, Nov. 14
8-8:45 a.m.
Move More Break
1:30-2:15 p.m.
VASCEPA® (icosapent ethyl): Elevating the Standard of Care (LS.07)
Sponsored by Amarin Parma, Inc.
1:30-2:15 p.m.
Jardiance® (empagliflozin) Tablets: The Impact of EMPA-REG OUTCOME (LS.08)
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA
1:30-2:15 p.m.
How to Identify and Manage the Hypertrophic Cardiomyopathy (HCM) That Is Hiding (LS.09)
Sponsored by MyoKardia, Inc.
1:30-2:15 p.m.
HFpEF: Heart Failure With Preserved Ejection Fraction (HFpEF): Pathophysiology vs Outcomes Are We Narrowing the Gap? (LS.10)
Sponsored by Novartis Pharmaceuticals Corporation
2:45-3:30 p.m.
Getting to the Heart of Managing Heart Failure: Unmet Medical Need in HFrEF (LS.11)
Sponsored by Amgen, Inc.
2:45-3:30 p.m.
Clinical Insights in Chronic CAD/PAD: Reducing the Risk of Major Cardiovascular Events (LS.12)
Sponsored by Janssen Pharmaceuticals, Inc.
3:30-4:15 p.m.*
A New Horizon to Optimize AF Outcomes: Emerging Data and Techniques in Hybrid Ablation (SS.04)
Sponsored by AtriCure
5-6:30 p.m.*
The Heart, the Kidney, and SGLT2 Inhibition: From Clinical Trials to Patient Care (SS.06)
Sponsored by AstraZeneca Pharmaceuticals
5-6:30 p.m.*
A Case-Based Session Hosted by CPC Clinical Research on Thromboprophylaxis in COVID-19 With Live Discussion Among Experts in the Field, Including Leaders of Ongoing COVID-19 Antithrombotic Trials (SS.10)
Sponsored by CPC Clinical Research
5-6:30 p.m.*
Identifying Undiagnosed Nonvalvular Atrial Fibrillation in the Age of Telehealth: Novel Screening Technologies and Stroke Prevention Strategies (SS.12)
Sponsored by Bristol-Myers Squibb and Pfizer Alliance
Sunday, Nov. 15
8-8:45 a.m.
Move More Break
1:30-2:15 p.m.
Optimizing LDL-C Management in Recent MI Patients: A Focus on Clinical Data (LS.13)
Sponsored by Amgen, Inc.
1:30-2:15 p.m.
Clinical Insights in NVAF: Reducing the Risk of Stroke and Systemic Embolism (LS.14)
Sponsored by Janssen Pharmaceuticals, Inc.
1:30-2:15 p.m.
Heart Failure With Preserved Ejection Fraction: Current Perspectives and Opportunities to Optimize Care Surrounding Hospitalization (LS.15)
Sponsored by Novartis Pharmaceuticals Corporation
1:30-2:15 p.m.*
Calcitropes, Myotropes and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF (SS.02)
Sponsored by Cytokinetics, Inc.
2:45-3:30 p.m.
Getting to the Heart of Managing Heart Failure: Advancements of Clinical Utility of HRQoL in HFrEF (LS.16)
Sponsored by Amgen, Inc.
2:45-3:30 p.m.
Improving Early Outcomes for the Post-AMI Patient: Cholesterol Efflux and the Role of ApoA-I in Plaque Stabilization (LS.17)
Sponsored by CSL Behring
5-6:30 p.m.*
Addressing the Impacts of Iron Deficiency in HF: Advances in Diagnosis and Management (SS.08)
Sponsored by American Regent
5-6:30 p.m.*
Improving Cardiovascular Outcomes by Decreasing Residual Risk (SS.13)
Sponsored by Amarin Pharma Inc.
5-6:45 p.m.*
National Heart, Lung, and Blood Institute (NHLBI) Company Showcase (SS.09)
Sponsored by National Heart, Lung, and Blood Institute
Monday, Nov. 16
8-8:45 a.m.
Move More Break
1:30-2:15 p.m.
An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C (LS.18)
Sponsored by Esperion Therapeutics, Inc.
1:30-2:15 p.m.
Intensive Lipid Management: Special Subgroups [Lp(a)] – Different Clinical Practices to Achieve the Same Therapeutic Targets (LS.19)
Sponsored by Kaneka Pharma America LLC
1:30-2:15 p.m.
Atherosclerotic Cardiovascular Disease (ASCVD) High Risk Assessment, Evaluation and Management (LS.20)
Sponsored by Novartis Pharmaceuticals Corporation
3:30-4:15 p.m.*
Mayo Clinic Cardiac Surgery Expertise in Surgical Treatment of Hypertrophic Cardiomyopathy, Aortic Aneurysms and Robotic Heart Surgery (SS.16)
Sponsored by Mayo Clinic Department of Cardiovascular Surgery
5-6:30 p.m.*
Antiplatelet Agent Updates: From Primary Prevention in CAD to Secondary Prevention of Stroke (SS.01)
Sponsored by AstraZeneca
5-6:30 p.m.*
Lowering LDL-C: When Statins Aren’t Enough (SS.14)
Sponsored by ESPERION Therapeutics, Inc.
Tuesday, Nov. 17
8-8:45 a.m.
Move More Break
1:30-2:15 p.m.
Role of Lipoprotein (a) in Atherosclerotic Cardiovascular Disease (LS.21)
Sponsored by Novartis Pharmaceuticals Corporation
2:30-3:15 p.m.
CCM® for Heart Failure – The Class Effect Assessing Heart Failure – How Are We Doing? Device Therapy for HF – Appropriate Patient Selection and Identification (LS.22)
Sponsored by Impulse Dynamics
5-6:30 p.m.*
Stepping Up Your Game for Management of Dyslipidemia (SS.03)
Sponsored by Amgen
5-6:30 p.m.*
The Role of Anticoagulants for Secondary Prevention in CAD and PAD Patients: When Should Therapy Be Initiated? (SS.15)
Sponsored by Janssen Scientific Affairs, LLC
Sessions noted with * indicate symposia. These events are not part of the official ScientificSessions as planned by the AHA Committee on Scientific Sessions Programming.
